{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:59:49Z","timestamp":1794959989915,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long-term safety (\u226512\u2009months) of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) or its receptor in migraine prevention by synthesising evidence from clinical trials and real-world studies. We focus on drug discontinuation due to adverse events and the type and frequency of adverse events. This is the first review to analyse the effects of the long-term use of all anti-CGRP (receptor) mAbs, aiming to provide novel insights for clinical practice and future treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Cochrane Library, and ClinicalTrials.gov for studies with \u226512\u2009months of anti-CGRP (receptor) mAb use between January 2013 and April 2025. A random-effects meta-analysis of proportions (logit transformation, inverse variance weighting, restricted maximum likelihood) was performed to estimate pooled discontinuation and adverse event rates. Risk of bias was assessed using the ROBINS-I score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From a total of 1,499 records, 14\u2009met the inclusion criteria and were eligible for data analysis. These 14 records corresponded to 11 individual studies with observational durations all exceeding 12\u2009months. Seven studies investigated erenumab, two eptinezumab, and one each fremanezumab and galcanezumab. All studies were judged to have a severe risk of bias due to their underlying design. The overall pooled proportion of treatment discontinuation for any reason among patients receiving anti-CGRP (receptor) mAbs was 23%, whereas the pooled proportion of discontinuation specifically due to adverse events was substantially lower at 3%. Time-trend analysis showed that adverse event\u2013related discontinuation remained low (&lt;5%) beyond the first year, while overall adverse event incidence was high at baseline (&gt;70%) but did not further increase with prolonged follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evidence on long-term use of anti-CGRP (receptor) mAbs over 12\u2009months remains limited, but our analysis indicates good tolerability with consistently low adverse event-related discontinuation, no emergent safety signals, and largely non-serious, stable adverse event profiles. However, heterogeneity and study-level bias warrant cautious interpretation, highlighting the need for long-term clinical studies and continued real-world surveillance (e.g. registries).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02256-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:03:29Z","timestamp":1767423809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review"],"prefix":"10.1186","volume":"27","author":[{"given":"Carolin Luisa","family":"Hoehne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Hendrik","family":"Overeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez-Del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ryliskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling","family":"Tronvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Headache Federation, EHF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"2256_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"2256_CR2","doi-asserted-by":"publisher","unstructured":"Hay SI, Ong KL, Santomauro DF, B A, Aalipour MA, Aalruz H et al (2025) Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023. A systematic analysis for the Global Burden of Disease Study 2023. Lancet S014067362501637X. https:\/\/doi.org\/10.1016\/S0140-6736(25)01637-X","DOI":"10.1016\/S0140-6736(25)01637-X"},{"key":"2256_CR3","doi-asserted-by":"publisher","first-page":"033310242513215","DOI":"10.1177\/03331024251321500","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S et al (2025) Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia 45:03331024251321500. https:\/\/doi.org\/10.1177\/03331024251321500","journal-title":"Cephalalgia"},{"key":"2256_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet 405:1014\u20131026. https:\/\/doi.org\/10.1016\/S0140-6736(25)00109-6","journal-title":"Lancet"},{"key":"2256_CR5","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/brainsci12121612","volume":"12","author":"JP Rissardo","year":"2022","unstructured":"Rissardo JP, Caprara ALF (2022) Gepants for acute and preventive migraine treatment: a narrative review. Brain Sci 12:1612. https:\/\/doi.org\/10.3390\/brainsci12121612","journal-title":"Brain Sci"},{"key":"2256_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/head.13379","volume":"58","author":"SJ Tepper","year":"2018","unstructured":"Tepper SJ (2018) History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache J Head Face Pain 58:238\u2013275. https:\/\/doi.org\/10.1111\/head.13379","journal-title":"Headache J Head Face Pain"},{"key":"2256_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"2256_CR8","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"2256_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s10194-024-01860-w","volume":"25","author":"H G\u00f6bel","year":"2024","unstructured":"G\u00f6bel H, Schlegel E, Jaeger K, Ortler S, Leist L (2024) Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON). J Headache Pain 25:157. https:\/\/doi.org\/10.1186\/s10194-024-01860-w","journal-title":"J Headache Pain"},{"key":"2256_CR10","doi-asserted-by":"publisher","first-page":"e209349","DOI":"10.1212\/WNL.0000000000209349","volume":"102","author":"U Reuter","year":"2024","unstructured":"Reuter U, Goadsby PJ, Ferrari MD, Da Silva Lima GP, Mondal S, Kalim J et al (2024) Efficacy and safety of erenumab in participants with episodic migraine in whom 2\u20134 prior preventive treatments had failed: LIBERTY 3-year study. Neurology 102:e209349. https:\/\/doi.org\/10.1212\/WNL.0000000000209349","journal-title":"Neurology"},{"key":"2256_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","volume":"93","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Reuter U, Goadsby PJ, Paiva Da Silva Lima G, Mondal S, Wen S et al (2022) Two-year efficacy and safety of erenumab in participants with episodic migraine and 2\u20134 prior preventive treatment failures: results from the liberty study. J Neurol Neurosurg Psychiatry 93:254\u2013262. https:\/\/doi.org\/10.1136\/jnnp-2021-327480","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2256_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y et al (2021) Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache J Head Face Pain 61:653\u2013661. https:\/\/doi.org\/10.1111\/head.14096","journal-title":"Headache J Head Face Pain"},{"key":"2256_CR13","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28:1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"key":"2256_CR14","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M, Paiva Da Silva Lima G, Hours-Zesiger P, Fernandes C et al (2021) Long-term efficacy and safety of erenumab: results from 64 weeks of the liberty study. Neurology 96. https:\/\/doi.org\/10.1212\/WNL.0000000000012029","DOI":"10.1212\/WNL.0000000000012029"},{"key":"2256_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein SD et al (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40:543\u2013553. https:\/\/doi.org\/10.1177\/0333102420912726","journal-title":"Cephalalgia"},{"key":"2256_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA et al (2019) Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39:1455\u20131464. https:\/\/doi.org\/10.1177\/0333102419854082","journal-title":"Cephalalgia"},{"key":"2256_CR17","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s40122-024-00658-7","volume":"13","author":"C Gaul","year":"2024","unstructured":"Gaul C, Gendolla A, Holle D, G\u00f6bel H, Koch M, Baufeld C et al (2024) Real-world experience of erenumab in patients with migraine in Germany: the spectre study. Pain Ther 13:1659\u20131678. https:\/\/doi.org\/10.1007\/s40122-024-00658-7","journal-title":"Pain Ther"},{"key":"2256_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","volume":"23","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R et al (2022) Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain 23:139. https:\/\/doi.org\/10.1186\/s10194-022-01507-8","journal-title":"J Headache Pain"},{"key":"2256_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-025-01994-5","volume":"26","author":"S Yoshida","year":"2025","unstructured":"Yoshida S, Imai N, Keicho M, Kamimura J, Moriya A, Yagi N et al (2025) Efficacy and continuability of 675 mg fremanezumab administration over 2 years. J Headache Pain 26:51. https:\/\/doi.org\/10.1186\/s10194-025-01994-5","journal-title":"J Headache Pain"},{"key":"2256_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","volume":"20","author":"K Hirata","year":"2021","unstructured":"Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H et al (2021) A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf 20:721\u2013733. https:\/\/doi.org\/10.1080\/14740338.2021.1866536","journal-title":"Expert Opin Drug Saf"},{"key":"2256_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR et al (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21:126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"key":"2256_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s10194-023-01688-w","volume":"24","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Gendolla A, Sperling B, Ettrup A, Josiassen MK et al (2023) Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. J Headache Pain 24:155. https:\/\/doi.org\/10.1186\/s10194-023-01688-w","journal-title":"J Headache Pain"},{"key":"2256_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"2256_CR24","doi-asserted-by":"publisher","first-page":"033310242312061","DOI":"10.1177\/03331024231206162","volume":"43","author":"K Aleksovska","year":"2023","unstructured":"Aleksovska K, Hershey AD, Deen M, De Icco R, Lee MJ, Diener H-C (2023) Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. grade tables elaborated by the ad hoc working group of the International Headache Society. Cephalalgia 43:03331024231206162. https:\/\/doi.org\/10.1177\/03331024231206162","journal-title":"Cephalalgia"},{"key":"2256_CR25","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","volume":"39","author":"D Xu","year":"2019","unstructured":"Xu D, Chen D, Zhu L, Tan G, Wang H, Zhang Y et al (2019) Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia 39:1164\u20131179. https:\/\/doi.org\/10.1177\/0333102419829007","journal-title":"Cephalalgia"},{"key":"2256_CR26","doi-asserted-by":"publisher","first-page":"033310242211370","DOI":"10.1177\/03331024221137091","volume":"43","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, De Icco R, Corrado M, Terhart M, Ailani J (2023) Open-label trials for CGRP-targeted drugs in migraine prevention: a narrative review. Cephalalgia 43:03331024221137091. https:\/\/doi.org\/10.1177\/03331024221137091","journal-title":"Cephalalgia"},{"key":"2256_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333. https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22","journal-title":"J Manag Care Pharm"},{"key":"2256_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-025-02040-0","volume":"26","author":"M Straburzy\u0144ski","year":"2025","unstructured":"Straburzy\u0144ski M, Kopyt D, Marschollek K, B\u0142aszczyk B, Kuca-Warnawin E, Kurowska W et al (2025) Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment. J Headache Pain 26:88. https:\/\/doi.org\/10.1186\/s10194-025-02040-0","journal-title":"J Headache Pain"},{"key":"2256_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells12010143","volume":"12","author":"AR Pavelic","year":"2022","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K (2022) Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells 12:143. https:\/\/doi.org\/10.3390\/cells12010143","journal-title":"Cells"},{"key":"2256_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (2024) The American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache J Head Face Pain 64:333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache J Head Face Pain"},{"key":"2256_CR31","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/head.14390","volume":"62","author":"D Kudrow","year":"2022","unstructured":"Kudrow D, Nguyen L, Semler J, Stroud C, Samaan K, Hoban DB et al (2022) A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist. Headache J Head Face Pain 62:1164\u20131176. https:\/\/doi.org\/10.1111\/head.14390","journal-title":"Headache J Head Face Pain"},{"key":"2256_CR32","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2024","unstructured":"Sun W, Li Y, Xia B, Chen J, Liu Y, Pang J et al (2024) Adverse event reporting of four anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front Pharmacol 14:1257282. https:\/\/doi.org\/10.3389\/fphar.2023.1257282","journal-title":"Front Pharmacol"},{"key":"2256_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/head.14962","volume":"65","author":"V Nikitina","year":"2025","unstructured":"Nikitina V, Santi Laurini G, Montanaro N, Motola D (2025) Postmarketing safety of migraine prophylactic monoclonal antibodies: an EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. Headache J Head Face Pain 65:1080\u20131094. https:\/\/doi.org\/10.1111\/head.14962","journal-title":"Headache J Head Face Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02256-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:02:25Z","timestamp":1781625745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02256-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this study does not involve direct human or animal subjects, and all data were extracted from previously published studies, ethical approval or informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors did not receive support from any organization for the submitted work. CLH has nothing to declare. LHO has nothing to declare. MSdR is the second vice president of the European Headache Federation. She has received personal fees as Speaker from Teva, Pfizer, Eli Lilly, Lundbeck and Organon. CD has received travel grants and honoraria from AstraZeneca, Merck & Co, Pfizer and Teva Pharmaceuticals and research grants from the International Headache Society and the Hellenic Neurology Society. RGG reports honoraria for consultant and\/or advisory boards from Allergan\/Abbvie, Astra Zeneca, Almirall, Bial, Biogen, Bristol-Myers Squibb, CMBE, FLOAT, Lilly, Lundbeck, Merk, Novartis, Novo Nordisk, Organon, Pfizer, Roche, Sanofi, Tecnifar and Teva; research funding from Funda\u00e7\u00e3o Ci\u00eancia Tecnologia (Project 29675, MigN2Treat, 02\/SAICT\/2017); Learning-Health, Luz Sa\u00fade (LiON, Luz Innovation on Neurosciences); Novartis-Sociedade Portuguesa de Cefaleias; Bolsa \u2013Projecto Centro de Investiga\u00e7\u00e3o Interdisciplinar em Sa\u00fade and UCP. JV received personal fees and non-financial support from Pfizer, Lilly, and Teva; personal fees from Novartis and Lundbeck; and grants and non-financial support from Allergan and AbbVie. FMA has received personal fees for lecturing and\/or participation in advisory boards from AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals; and research grants from the Lundbeck Foundation; he is currently the president of Danish Headache Society and board member of the European Headache Federation and associate editor for Frontiers In Pain Research, Frontiers In Neurology, and Acta Neurologica Scandinavica. CL has received consulting fees and honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva. CL participated in clinical trials as the principal investigator for Eli Lilly. Intellectual Christian Lampl is past-president of the European Headache Federation and Associate Editor for The Journal of Headache and Pain. KR has received personal fees for lectures\/advisory boards: Novartis, Abbvie, TEVA, Lundbeck, Pfizer, Viatris, Berlin Chemie. ET has received personal fees for lectures\/advisory boards: Novartis, Eli Lilly, Abbvie, TEVA, Roche, Lundbeck, Pfizer, Biogen, Organon. Consultant for and owner of stocks and IP in Man & Science. Stocks and IP in Nordic Brain Tech. Stocks in Keimon Medical. Non-personal research grants from several sources, including Norwegian Research Council, KlinBeForsk, EU. Commissioned research (non-personal): Lundbeck. GC serves as Associate Editor of The Journal of Headache and Pain, Cephalalgia, Cephalalgia Reports, Frontiers in Neurology (Neurotechnology section), BMC Neurology (Pain section), Frontiers in Human Neuroscience (Brain Imaging and Stimulation section), Headache and Pain Research, Confinia Cephalalgica. He has received honoraria as a moderator from AbbVie, Pfizer, and Eli-Lilly, has received consulting fees from AbbVie, Eli-Lilly, and Pfizer, and has been the PI in trials sponsored by Pfizer and AbbVie. He has received research grants from AbbVie. PRH reports honoraria for educational and advisory purposes from Allergan, Novartis, Pfizer, Eli Lilly and Co and Teva as well as research funding from Eli Lilly and Company, Amgen, and Cellgene\/Bristol Myers Squibb. Intellectual as a member at large of the European Headache Federation and associate editor roles for The Journal of Headache and Pain, Cephalalgia and The British Journal of Pharmacology. AMvdB received honoraria, research and\/or travel grants from Allergan\/Abbvie, Amgen\/Novartis, Eli Lilly, Organon, Pfizer, Satsuma and Teva as principal investigator. Intellectual as president of the European Headache Federation, associate editor for The Journal of Headache and Pain. PM serves as Editor-in-Chief of The Journal of Headache and Pain and SN Comprehensive Clinical Medicine and also serves as Expert EU Member at European Medicines Agency. UR has no personal fees to report. Institutional fees from Amgen, Abbvie, Lilly, Lundbeck, Novartis, Pfizer, Medscape, Sand Teva, and research funding from Novartis. UR is associate editor of the JHP and the vice president of the EHF.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}